Intravenous Line Phase-Wrap Artifact at Bilateral Axial 3-T Breast MRI: Identification, Analysis, and Solution.
Journal
Radiology. Imaging cancer
ISSN: 2638-616X
Titre abrégé: Radiol Imaging Cancer
Pays: United States
ID NLM: 101765309
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
27
01
2020
revised:
06
05
2020
accepted:
16
06
2020
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
26
8
2021
Statut:
epublish
Résumé
To understand and remove the source of a phase-wrap artifact produced by residual contrast agent in the intravenous line during acquisition of bilateral axial 3-T dynamic contrast material-enhanced (DCE) breast MRI. A two-part study involved a phantom experiment, followed by an institutional review board approved clinical intervention, to evaluate the phase-wrap artifact at MRI. A phantom model evaluated artifact production by using an intravenous line filled with fluids with varying concentrations of gadolinium-based contrast agent (0, 0.4, 0.8, 1.2, 1.6, and 2 mmol/mL) and by positioning the simulated intravenous line within several fields of view (FOV) at 3-T MRI in breast coils. Next, a clinical assessment was performed with a total of 400 patients (control group:interventional group, 200:200) to determine the effect of taping the intravenous line to the patients' backs. Breast MR images were assessed blindly for the presence of the artifact. Software was used for statistical analysis with a In the phantom model, the artifact was produced only with a 0.4 mmol/mL gadolinium concentration and when the tubing was either close to the edge or within a FOV of 350-450 mm. In the clinical experiment, the artifact was more prevalent in the retrospective control group than in the prospective intervention group (52.5% [105 of 200] vs 22% [44 of 200]; The presence of phase-wrap artifacts can be reduced by moving the contrast agent intravenous line out of the FOV during acquisition by taping it to a patient's back during bilateral axial 3-T DCE breast MRI.
Identifiants
pubmed: 33778747
doi: 10.1148/rycan.2020200004
pmc: PMC7983766
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e200004Informations de copyright
2020 by the Radiological Society of North America, Inc.
Déclaration de conflit d'intérêts
Disclosures of Conflicts of Interest: E.S. disclosed no relevant relationships. Y.A. disclosed no relevant relationships. J.M.G. disclosed no relevant relationships. S.F. disclosed no relevant relationships. T.A.K. disclosed no relevant relationships. T.S. disclosed no relevant relationships.
Références
J Magn Reson Imaging. 2007 May;25(5):884-99
pubmed: 17457803
Radiographics. 1998 Nov-Dec;18(6):1499-521
pubmed: 9821197
Radiology. 2019 Sep;292(3):520-536
pubmed: 31361209
Radiol Clin North Am. 2010 Sep;48(5):1013-42
pubmed: 20868898
Insights Imaging. 2018 Jun;9(3):325-335
pubmed: 29616496
Med Phys. 2015 May;42(5):2268-75
pubmed: 25979021
J Neuroophthalmol. 1997 Mar;17(1):12-7
pubmed: 9093955
AJNR Am J Neuroradiol. 1992 May-Jun;13(3):879-84
pubmed: 1590186
JAMA. 2004 Sep 15;292(11):1317-25
pubmed: 15367553
Radiology. 2017 Jun;283(3):692-701
pubmed: 27788035
Radiology. 2000 Apr;215(1):267-79
pubmed: 10751498
J Am Coll Radiol. 2010 Jan;7(1):18-27
pubmed: 20129267
Radiology. 2007 Aug;244(2):381-8
pubmed: 17641362
Radiographics. 2006 Sep-Oct;26(5):1469-84
pubmed: 16973776
Eur Radiol. 2017 Jul;27(7):2737-2743
pubmed: 27807699
AJR Am J Roentgenol. 1989 Feb;152(2):385-6
pubmed: 2783517
Radiographics. 2007 Oct;27 Suppl 1:S131-45
pubmed: 18180223
Eur Radiol. 2008 Jul;18(7):1307-18
pubmed: 18389253
Eur Radiol. 2015 Dec;25(12):3669-78
pubmed: 26002130
Radiographics. 2007 Oct;27 Suppl 1:S165-82
pubmed: 18180225